Himax Auto Restocking Drives 2Q26 Guidance Beat, but 2H Margin and CPO Uncertainty Limit Upside

Core Conclusion

Himax’s 2Q26 revenue guidance (10–13% Q/Q growth) and gross margin (~32%) both surpassed expectations, driven by automotive customer inventory replenishment and new project ramps. However, no end-demand recovery is visible in auto or consumer electronics, and rising material costs threaten margin sustainability. CPO contributions remain negligible in 2026, with meaningful volume only from 2027. At 25x 2027e EPS—one standard deviation above the historical average—the stock fully prices in the restocking tailwind. Maintain Equal-weight with a $17.4 target price (2% downside).

What the Market May Underestimate

The market likely overestimates the durability of the auto restocking cycle. Inventory replenishment, not end-market improvement, drove the 2Q beat. Once restocking normalizes, revenue momentum could fade. It also underestimates the drag from cost inflation: although April price hikes began, full pass-through is uncertain. Gross margin in 2H faces greater downside than upside as cost increases accelerate. CPO is unlikely to contribute meaningfully to earnings until 2027–2028, given product qualification timelines.

Evidence Chain

Claim 1: 2Q26 guidance beat is led by auto restocking, not structural demand improvement.

• Revenue guided +10–13% Q/Q (vs. MSe of flat); gross margin ~32% (vs. MSe 30.2%).
• SMDDIC (auto DDI/TDDI) guided high-teens Q/Q growth, driven by replenishment and new project ramps.
• LDDIC to decline high-teens Q/Q due to earlier TV pull-ins.
• Investment implication: The beat is inventory-driven; without end-demand recovery, the restocking boost may exhaust in 2H, leaving revenue at risk of sequential flattening.

Claim 2: CPO revenue is negligible in 2026; volume ramp starts only in 2027–2028.

• NVIDIA CPO optical engine production estimated at 600k–1mn units in 2026, with Himax as single source for FOCI capturing ~40% share → less than 1% of Himax total revenue.
• Gen 1 and Gen 2 products with FOCI begin small-sample shipments in 2H26; mass production expected 2027.
• Investment implication: CPO upside is a 2027+ story; current valuation already includes optimistic 2027e EPS of $0.72, leaving limited room for near-term CPO re-rating.

Claim 3: Gross margin faces rising cost pressure despite April price hikes.

• 1Q26 gross margin of 30.4% was flat Q/Q and at high end of guidance.
• Full-year 2026 gross margin forecast at 32.0%, only +1.5ppts vs. 2025’s 30.5%, despite price adjustments.
• Management noted that if cost inflation is not fully offset, margin could contract.
• Investment implication: Margin expansion is modest and fragile; any shortfall on pricing pass-through could compress 2H margins below the 32% target.

Claim 4: Current valuation reflects the restocking beat and 2027 optimism.

• Stock trades at 25x 2027e EPS, above historical average of 16.6x and near +1 standard deviation (25x).
• Residual income model yields $17.4 target (24x 2027e EPS), ~2% below current price of $17.79.
• Investment implication: Upside from here requires either faster-than-expected end-demand recovery or a CPO volume surprise in 2027—both uncertain.

Key Risks

• Cost inflation and pricing pass-through failure: Material and foundry costs continue rising; if customers resist price increases, gross margin will miss forecasts.
• CPO ramp delays: Volume production for Gen 1/Gen 2 may slip beyond 2027, pushing the growth inflection further out.
• Chinese DDIC competition: More Chinese foundry capacity is coming online, pressuring market share and pricing in core driver ICs.
• Post-restocking demand slump: Auto and consumer end-markets show no material pickup; once inventory normalization completes, revenue could revert to sequential declines.

Valuation or Trading Implication

The $17.4 price target is derived from a residual income model (9.9% cost of equity, 8.0% medium-term growth, 3.4% terminal growth). At current $17.79, the stock prices in 25x 2027e EPS, leaving only 2% downside. Prefer FOCI as a purer CPO proxy given its direct exposure to mass production volume. Hold Himax at Equal-weight and wait for clearer signals on 2H margin trajectory and CPO orders before re-engaging.

Appendix: CPO Revenue Contribution to Himax (2026e–2028e)